
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition Inc. is positioned for a positive financial trajectory due to its focus on the commercialization of ZUNVEYL, which addresses a critical need in the market for neurodegenerative diseases. Expectations of a significant advancement in sales as contracting is implemented, combined with a forecasted acceleration in 2026 that could broaden outreach to neurologists, support a favorable outlook for revenue growth. Additionally, a projected year-end 2025 cash balance of approximately $63 million suggests that the company has adequate financial resources to sustain operations towards achieving profitability.
Bears say
Alpha Cognition Inc. has reduced its net sales forecast for 2025 to $5.7 million from $11.7 million, reflecting anticipated delays in contracting and reimbursement processes for its lead product, ZUNVEYL. Potential risks include challenges in launching ZUNVEYL timely, slow market uptake due to competitive pressures, and the likelihood of clinical development setbacks, all of which could hinder future growth. Additionally, concerns about medium- to long-term equity dilution impact the perception of the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares